A formulation of AbbVie’s blockbuster wrinkle treatment, acquired through its buyout of Allergan, has failed a mid-stage trial as a potential fix for overactive bladder and urinary incontinence.
The FDA in 2013 approved the use of onabotulinumtoxinA (Botox) via injection into the bladder as a treatment for overactive bladder in adults who can’t take or whose condition doesn’t respond to anticholinergic medications. In 2016, Allergan struck a deal with UroGen Pharma (NASDAQ: URGN) that gave it rights to the biotech’s reverse-thermal hydrogel, or RTGel, technology to test in combination with Botox and other toxins produced by the Clostridium family of... Read more »
Author: Sarah de Crescenzo
Date : 2020-08-27T21:30:58.000Z